LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells

Salman Yaylaz, Burcu; EMRENCE, ZELIHA; Sariman, Melda; ABACI, NESLIHAN; Gulec, Cagri; Sırma Ekmekci, Sema; EKMEKCI, CUMHUR GOKHAN

doi:10.4274/tjh.galenos.2020.2020.0144

LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells

Sema Sırma EKMEKCİ, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Zeliha EMRENCE, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Neslihan ABACI, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Melda SARIMAN, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Burcu SALMAN, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Cumhur Gökhan EKMEKCİ, (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Çağrı GÜLEÇ (İstanbul Üniversitesi, Aziz Sancar Deneysel Tıp Enstitüsü, Genetik Anabilim Dalı, İstanbul, Türkiye)

Turkish Journal of Hematology

3 0

Yıl: 2020 Cilt: 37 Sayı: 4 Sayfa Aralığı: 226 - 233 Metin Dili: İngilizce DOI: 10.4274/tjh.galenos.2020.2020.0144 İndeks Tarihi: 30-06-2021

LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells

Öz:

Objective: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressivedisease resulting from the accumulation of genetic changes that affectthe development of T-cells. The precise role of lymphoid enhancerbinding factor 1 (LEF1) in T-ALL has been controversial since bothoverexpression and inactivating LEF1 mutations have been reportedto date. Here, we investigate the potential gene targets of LEF1 in theJurkat human T-cell leukemia cell line.Materials and Methods: We used small interfering RNA (siRNA)technology to knock down LEF1 in Jurkat cells and then comparedthe gene expression levels in the LEF1 knockdown cells with nontargeting siRNA-transfected and non-transfected cells by employingmicroarray analysis.Results: We identified DHRS2, a tumor suppressor gene, as the mostsignificantly downregulated gene in LEF1 knockdown cells, and wefurther confirmed its downregulation by real-time quantitativepolymerase chain reaction (qRT-PCR) in mRNA and at protein level bywestern blotting.Conclusion: Our results revealed that DHRS2 is positively regulated byLEF1 in Jurkat cells, which indicates the capability of LEF1 as a tumorsuppressor and, together with previous reports, suggests that LEF1exhibits a regulatory role in T-ALL via not only its oncogenic targetsbut also tumor suppressor genes.

Anahtar Kelime:

İnsan Akut Lenfoblastik Lösemi T-hücre Soyu Jurkat hücrelerinde LEF1, DHRS2 Gen Ekspresyonunu İndükler

Öz:

Amaç: T-hücreli akut lenfoblastik lösemi (T-ALL), T-hücrelerinin gelişimini etkileyen genetik değişikliklerin birikmesinden kaynaklanan agresif bir hastalıktır. Bugüne kadar lymphoid enhancer-binding factor 1’in (LEF1) hem inaktive edici mutasyonları hem de aşırı ekspresyonu bildirildiğinden T-ALL gelişiminde rolü tartışmalıdır. Bu çalışmada, insan T hücreli lösemi hücre soyu olan Jurkat hücrelerinde LEF1’in potansiyel hedef genleri araştırıldı. Gereç ve Yöntemler: Jurkat hücrelerinde küçük engelleyici RNA (siRNA) teknolojisi ile LEF1 baskılandı ve mikroarray analizi ile LEF1 baskılanmış hücrelerdeki gen ekspresyon seviyeleri, negatif kontrol siRNA (hedefsiz siRNA) ile transfekte edilmiş hücrelerdeki gen ekspresyon seviyeleri ile karşılaştırıldı. Bulgular: LEF1 baskılanmış hücrelerde en önemli seviyede expresyonu azalan gen tümör baskılayıcı DHRS2 geni olarak belirlendi. Ayrıca bu bulgu hem mRNA seviyesinde gerçek zamanlı kantitatif polimeraz zincir reaksiyonu (qRT-PCR) ile hem de protein seviyesinde western blot ile doğrulandı. Sonuç: Bu bulgular DHRS2’nin Jurkat hücrelerinde LEF1 tarafından pozitif olarak düzenlendiğini göstererek LEF1’in tümör baskılayıcı kapasitesi olduğuna işaret etmektedir ve daha önceki çalışmalarda bildirilen sonuçlarla birlikte, LEF1’in hem onkojenik hedefleri hem de tümör baskılayıcı hedefleri aracılığıyla T-ALL’de düzenleyici bir rol oynadığını ileri sürmektedir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. McMahon CM, Luger S. Relapsed T cell ALL: current approaches and new directions. Curr Hematol Malig Rep 2019;14;83-93.
2. Bongiovanni D, Saccomani V, Piovan E. Aberrant signaling pathways in T-cell acute lymphoblastic leukemia. Int J Mol Sci 2017;18:1904.
3. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003;21:3616-3622.
4. Oudot C, Auclerc MF, Levy V, Porcher R, Piguet C, Perel Y, Gandemer V, Debre M, Vermylen C, Pautard B, Berger C, Schmitt C, Leblanc T, Cayuela JM, Socie G, Michel G, Leverger G, Baruchel A. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study. J Clin Oncol 2008;26:1496-1503.
5. Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 2012;122:3398-3406.
6. Weng AP. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006;20:2096-2109.
7. Fogelstrand L, Staffas A, Wasslavik C, Sjögren H, Söderhäll S, Frost BM, Forestier E, Degerman S, Behrendtz M, Heldrup J, Karrman K, Johansson B, Heyman M, Abrahamsson J, Palmqvist L. Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-all treated according to the NOPHO ALL-1992 and ALL-2000 protocols. Pediatr Blood Cancer 2014;61:424-430.
8. Roti G, Stegmaier K. Targeting NOTCH1 in hematopoietic malignancy. Crit Rev Oncog 2011;16:103-115.
9. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-850.
10. Grumolato L, Liu G, Haremaki T, Mungamuri SK, Mong P, Akiri G, LopezBergami P, Arita A, Anouar Y, Mlodzik M, Ronai ZA, Brody J, Weinstein DC, Aaronson SA. β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS Genet 2013;9:e1003603.
11. Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ, Heilmeier B, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, FeuringBuske M, Buske C. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med 2008;205:515-522.
12. Gutierrez A Jr, Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM 3rd, Slager SL, Kay NE, Jelinek DF. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010;116:2975-2983.
13. Metzeler KH, Heilmeier B, Edmaier KE, Rawat VP, Dufour A, Döhner K, Feuring-Buske M, Braess J, Spiekermann K, Büchner T, Sauerland MC, Döhner H, Hiddemann W, Bohlander SK, Schlenk RF, Bullinger L, Buske C. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. Blood 2012;120:2118-2126.
14. Kühnl A, Gökbuget N, Kaiser M, Schlee C, Stroux A, Burmeister T, Mochmann LH, Hoelzer D, Hofmann WK, Thiel E, Baldus CD. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood 2011;118:6362-6367.
15. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, Gotlib J, Li K, Manz MG, Keating A, Sawyers CL, Weissman IL. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-667.
16. Guo X, Zhang R, Liu J, Li M, Song C, Dovat S, Li J, Ge Z. Characterization of LEF1 high expression and novel mutations in adult acute lymphoblastic leukemia. PLoS One 2015;10:e0125429.
17. Wu W, Zhu H, Fu Y, Shen W, Miao K, Hong M, Xu W, Fan L, Young KH, Liu P, Li J. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid. Oncotarget 2016;7:21631.
18. Jia M, Zhao HZ, Shen HP, Cheng YP, Luo ZB, Li SS, Zhang JY, Tang YM. Overexpression of lymphoid enhancer binding factor 1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia. Int J Lab Hematol 2015;37:631-640.
19. Albano F, Zagaria A, Anelli L, Orsini P, Minervini CF, Impera L, Casieri P, Coccaro N, Tota G, Brunetti C, Minervini A, Pastore D, Carluccio P, Mestice A, Cellamare A, Specchia G. Lymphoid enhancer binding factor-1 (LEF1) expression as a prognostic factor in adult acute promyelocytic leukemia. Oncotarget 2014;5:649.
20. Fu Y, Zhu H, Wu W, Xu J, Chen T, Xu B, Qian S, Li J, Liu P. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia. Leuk Lymphoma 2014;55:371-377.
21. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010;115:2845-2851.
22. Noronha EP, Marques LVC, Andrade FG, Thuler LCS, Terra-Granado E, Pombode-Oliveira MS; Brazilian Collaborative Study Group of Acute Leukemia. The profile of immunophenotype and genotype aberrations in subsets of pediatric T-cell acute lymphoblastic leukemia. Front Oncol 2019;9:1-10.
23. Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol 2016;1418:93-110.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 199;557:289- 300.
25. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
26. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009;37:1-13.
27. Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: More genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res 2019;47:419-426.
28. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 2000;28:27-30.
29. Shafqat N, Shafqat J, Eissner G, Marschall HU, Tryggvason K, Eriksson U, Gabrielli F, Lardy H, Jörnvall H, Oppermann U. Hep27, a member of the short-chain dehydrogenase/reductase family, is an NADPH-dependent dicarbonyl reductase expressed in vascular endothelial tissue. Cell Mol Life Sci 2006:63:1205-1213.
30. Zhou Y, Wang L, Ban X, Zeng T, Zhu Y, Li M, Guan XY, Li Y. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma. Oncogene 2018;37:1086-1094.
31. Mutirangura A, Pornthanakasem W, Sriuranpong V, Supiyaphun P, Voravud N. Loss of heterozygosity on chromosome 14 in nasopharyngeal carcinoma. Int J Cancer 1998;78:153-156.
32. Cheng Y, Ko JMY, Lung HL, Lo PHY, Stanbridge EJ, Lung ML. Monochromosome transfer provides functional evidence for growth-suppressive genes on chromosome 14 in nasopharyngeal carcinoma. Genes Chromosom Cancer 2003;37:359-368.
33. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S. Highresolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. Genes Chromosom Cancer 2000;27:387-391.
34. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, Kordek R, Miettinen M. Chromosomal aberrations in malignant gastrointestinal stromal tumors. Cancer Genet Cytogenet 2001;128:24-30.
35. Goeze A, Schlüns K, Wolf G, Thäsler Z, Petersen S, Petersen I. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol 2002;196:8-16.
36. Fang L, Cheng Q, Liu W, Zhang J, Ge Y, Zhang Q, Li L, Liu J, Zheng J. Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell. Cancer Biol Ther 2016;17:664-673.
37. Deisenroth C, Thorner AR, Enomoto T, Perou CM, Zhang Y. Mitochondrial HEP27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol 2010;30:3981-3993.
38. Oda T, Sekimoto T, Kurashima K, Fujimoto M, Nakai A, Yamashita T. Acute HSF1 depletion induces cellular senescence through the MDM2-p53-p21 pathway in human diploid fibroblasts. J Cell Sci 2018;131:jcs210724.
39. Han Y, Song C, Wang J, Tang H, Peng Z, Lu S. HOXA13 contributes to gastric carcinogenesis through DHRS2 interacting with MDM2 and confers 5-FU resistance by a p53-dependent pathway. Mol Carcinog 2018;57:722-734.
40. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000:10:94- 99.
41. Damalas A. Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J 1999;18:3054-3063.
42. Damalas A. Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J 2001;20:4912-4922.
43. Niemann C, Owens DM, Schettina P, Watt FM. Dual role of inactivating Lef1 mutations in epidermis: tumor promotion and specification of tumor type. Cancer Res 2007;67:2916-2921.
44. Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M. P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines. J Clin Invest 1993;91:2111-2117.
45. Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, Tsuruda K, Tsukasaki K, Tomonaga M, Hirakata Y, Kamihira S. Impact of p53 aberration on the progression of adult T-cell leukemia/lymphoma. Cancer Lett 2006;234:249-255.
46. Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood 2014;124:251-258.
47. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O’Neil J, Neuberg D, Weng AP, Aster JC, Sigaux F, Soulier J, Look AT, Young RA, Califano A, Ferrando AA. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006;103:18261-18266.

APA	Sırma Ekmekci S, EMRENCE Z, ABACI N, Sariman M, Salman Yaylaz B, EKMEKCI C, Gulec C (2020). LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. , 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
Chicago	Sırma Ekmekci Sema,EMRENCE ZELIHA,ABACI NESLIHAN,Sariman Melda,Salman Yaylaz Burcu,EKMEKCI CUMHUR GOKHAN,Gulec Cagri LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. (2020): 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
MLA	Sırma Ekmekci Sema,EMRENCE ZELIHA,ABACI NESLIHAN,Sariman Melda,Salman Yaylaz Burcu,EKMEKCI CUMHUR GOKHAN,Gulec Cagri LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. , 2020, ss.226 - 233. 10.4274/tjh.galenos.2020.2020.0144
AMA	Sırma Ekmekci S,EMRENCE Z,ABACI N,Sariman M,Salman Yaylaz B,EKMEKCI C,Gulec C LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. . 2020; 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
Vancouver	Sırma Ekmekci S,EMRENCE Z,ABACI N,Sariman M,Salman Yaylaz B,EKMEKCI C,Gulec C LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. . 2020; 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
IEEE	Sırma Ekmekci S,EMRENCE Z,ABACI N,Sariman M,Salman Yaylaz B,EKMEKCI C,Gulec C "LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells." , ss.226 - 233, 2020. 10.4274/tjh.galenos.2020.2020.0144
ISNAD	Sırma Ekmekci, Sema vd. "LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells". (2020), 226-233. https://doi.org/10.4274/tjh.galenos.2020.2020.0144

APA	Sırma Ekmekci S, EMRENCE Z, ABACI N, Sariman M, Salman Yaylaz B, EKMEKCI C, Gulec C (2020). LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. Turkish Journal of Hematology, 37(4), 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
Chicago	Sırma Ekmekci Sema,EMRENCE ZELIHA,ABACI NESLIHAN,Sariman Melda,Salman Yaylaz Burcu,EKMEKCI CUMHUR GOKHAN,Gulec Cagri LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. Turkish Journal of Hematology 37, no.4 (2020): 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
MLA	Sırma Ekmekci Sema,EMRENCE ZELIHA,ABACI NESLIHAN,Sariman Melda,Salman Yaylaz Burcu,EKMEKCI CUMHUR GOKHAN,Gulec Cagri LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. Turkish Journal of Hematology, vol.37, no.4, 2020, ss.226 - 233. 10.4274/tjh.galenos.2020.2020.0144
AMA	Sırma Ekmekci S,EMRENCE Z,ABACI N,Sariman M,Salman Yaylaz B,EKMEKCI C,Gulec C LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. Turkish Journal of Hematology. 2020; 37(4): 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
Vancouver	Sırma Ekmekci S,EMRENCE Z,ABACI N,Sariman M,Salman Yaylaz B,EKMEKCI C,Gulec C LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells. Turkish Journal of Hematology. 2020; 37(4): 226 - 233. 10.4274/tjh.galenos.2020.2020.0144
IEEE	Sırma Ekmekci S,EMRENCE Z,ABACI N,Sariman M,Salman Yaylaz B,EKMEKCI C,Gulec C "LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells." Turkish Journal of Hematology, 37, ss.226 - 233, 2020. 10.4274/tjh.galenos.2020.2020.0144
ISNAD	Sırma Ekmekci, Sema vd. "LEF1 Induces DHRS2 Gene Expression in Human Acute Leukemia Jurkat T-Cells". Turkish Journal of Hematology 37/4 (2020), 226-233. https://doi.org/10.4274/tjh.galenos.2020.2020.0144